In conclusion, our results expand current knowledge on the beneficial effects arising from the pharmacological modulation of NLRP3 inflammasome in experimental colitis (Pellegrini et al., 2017b), suggesting that the direct and irreversible inhibition of NLRP3 inflammasome complex could represent a more viable approach to the medical management of bowel inflammation than IL-1β receptor blockade or caspase-1 inhibition (see Figure 5). The gene discussed is NLRP3; the disease is colitis.